Edesa Biotech, Inc.

NASDAQ:EDSA

Biotechnology

Healthcare
$5.75 +1.31%

+$0.09 today

Market cap
$55.39M
Beta
1.07
P/E (TTM)
-5.5
EPS (TTM)
-$1.27
52W Low $0.72High $20.32

Volume 0.07M

Average 0.62M

EDSA Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Edesa Biotech, Inc.NASDAQ: EDSA

Research & Development · Q2 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q2 FY2026 research & development of $2.77M rose 471.4% year over year, ahead of the +141.7% change in trailing-twelve-month research & development. Sequentially, it rose 146.0% from the prior quarter. Over 3 fiscal years it compounded at -35.0% a year.

Context

  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +471.4% holds above the trailing-twelve-month pace of +141.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.77M+146.0% QoQ
Last fiscal yearSep 2025
$3.67M+27.3% YoY
LTMMar 2026
$6.06M+141.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+471.4%——
1 year+27.3%——
3-year CAGR-35.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
3.67M USD
Year-over-year change
+27.3%
4-year CAGR
-32.8%

Research & Development vs competitors

How EDSA compares with its peers on the latest reported figures

  • EDSA's LTM Mar 2026 research & development of $6.06M is the lowest of the 2 companies compared; the peer median is $22.1M.
  • Its year-over-year change of +141.7% is the lowest of 2, against a peer median of +292.9%.
  • Over three fiscal years its annual growth of -35.0% compares with a peer median of +39.4%.
EDSA Competitors Peer median
Research & Development for EDSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DWTXDogwood Therapeutics, Inc.LTM Mar 2026$22.1M +292.9%+39.4%—
EDSAEdesa Biotech, Inc.LTM Mar 2026$6.06M +141.7%-35.0%—
Peer median (excluding EDSA) $22.1M+292.9%+39.4%—

Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue118.79K118.19K183.47K186.05K119.27K
Gross Profit(118.79K)(118.19K)(183.47K)(186.05K)(119.27K)
Gross Margin—————
Research & Development17.95M13.34M4.79M2.88M3.67M
Selling, General & Admin5.73M5.04M4.43M4.13M4.24M
Operating Expenses23.68M18.37M9.22M7.01M7.79M
Depreciation & Amortization118.79K118.19K183.47K186.05K119.27K
EBITDA(13.22M)(17.43M)(8.19M)(5.98M)(7.07M)
EBITDA Margin—————
Operating Income(23.68M)(18.37M)(9.22M)(7.01M)(7.91M)
Operating Margin—————
Interest Income11.17K64289.85K153.5K2.56K
Interest Expense00000
Other Income / Expenses10.34M822.67K849.14K845.5K726.84K
Income Before Tax(13.34M)(17.55M)(8.37M)(6.17M)(7.18M)
Pre-Tax Margin—————
Income Tax Expense800800800800800
Net Income(13.34M)(17.55M)(8.37M)(6.17M)(7.19M)
Net Margin—————
EPS (Basic)(7.74)(8.37)(2.93)(1.93)(1.27)
EPS (Diluted)(7.73)(8.37)(2.93)(1.93)(1.27)
Weighted Avg Shares1.73M2.1M2.86M3.2M5.68M
Weighted Avg Shares (Diluted)1.73M2.1M2.86M3.2M5.68M

Edesa Biotech, Inc.

NASDAQ:EDSA

Intrinsic Alpha fair value

Locked

Current Price

$5.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.